Skip to main content
Swing Capital

Mankind Pharma Ltd

NSE: MANKIND BSE: 543904Pharma

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

₹2,495
52W: ₹1910 — ₹2727
PE 58.4 · Book ₹376 · +564% vs book
Market Cap₹1,03,001 Cr
Stock P/E58.4Price to Earnings
ROCE15%Return on Capital
ROE13.9%Return on Equity
Div. Yield0.04%Face Value ₹1

Weaknesses

  • −Promoter holding has decreased over last 3 years: -3.84%

Shareholding Pattern

Promoters72.66%
FIIs10.24%
DIIs14.46%
Public2.63%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters74.87%74.87%72.71%▼2.272.7%▼0.072.67%▼0.072.67%72.66%▼0.072.66%
FIIs11.58%12.37%▲0.813.34%▲1.012.92%▼0.413.07%▲0.212.83%▼0.211.34%▼1.510.24%▼1.1
DIIs9.94%9.91%▼0.011.05%▲1.111.47%▲0.411.5%▲0.011.91%▲0.413.26%▲1.314.46%▲1.2
Public3.61%2.86%▼0.82.89%▲0.02.89%2.75%▼0.12.57%▼0.22.75%▲0.22.63%▼0.1

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales2,2602,2092,0072,4132,5442,4142,1272,5412,6092,633
Expenses1,6621,6361,4821,8371,7811,6681,6501,8681,9161,854
Operating Profit598573526576763746477673693778
OPM %26%26%26%24%30%31%22%26%27%30%
Net Profit473487468506645412382413459449
EPS ₹11.812.1611.6812.6216.119.999.271011.1210.89

AI Insights

Revenue Trend

TTM revenue at ₹9,909Cr, up 4.3% YoY. OPM at 26%.

Debt Position

Borrowings at ₹7,248Cr. Debt-to-equity ratio: 0.47x. Healthy balance sheet.

Capex Cycle

CWIP at ₹248Cr (7% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 14.46% (+9.81pp change). FIIs: 10.24% (+6.06pp change). Promoters hold 72.66%.

Margin & Efficiency

ROCE improving from 0% (Mar 2018) to 15% (Mar 2025). Working capital days: -48.

Valuation

PE 58.4x with 15% ROCE. Price is 564% above book value of ₹376. Dividend yield: 0.04%.

Recent Announcements